» Articles » PMID: 33971933

Accessing Routinely Collected Health Data to Improve Clinical Trials: Recent Experience of Access

Overview
Journal Trials
Publisher Biomed Central
Date 2021 May 11
PMID 33971933
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Routinely collected electronic health records (EHRs) have the potential to enhance randomised controlled trials (RCTs) by facilitating recruitment and follow-up. Despite this, current EHR use is minimal in UK RCTs, in part due to ongoing concerns about the utility (reliability, completeness, accuracy) and accessibility of the data. The aim of this manuscript is to document the process, timelines and challenges of the application process to help improve the service both for the applicants and data holders.

Methods: This is a qualitative paper providing a descriptive narrative from one UK clinical trials unit (MRC CTU at UCL) on the experience of two trial teams' application process to access data from three large English national datasets: National Cancer Registration and Analysis Service (NCRAS), National Institute for Cardiovascular Outcomes Research (NICOR) and NHS Digital to establish themes for discussion. The underpinning reason for applying for the data was to compare EHRs with data collected through case report forms in two RCTs, Add-Aspirin (ISRCTN 74358648) and PATCH (ISRCTN 70406718).

Results: The Add-Aspirin trial, which had a pre-planned embedded sub-study to assess EHR, received data from NCRAS 13 months after the first application. In the PATCH trial, the decision to request data was made whilst the trial was recruiting. The study received data after 8 months from NICOR and 15 months for NHS Digital following final application submission. This concluded in May 2020. Prior to application submission, significant time and effort was needed particularly in relation to the PATCH trial where negotiations over consent and data linkage took many years.

Conclusions: Our experience demonstrates that data access can be a prolonged and complex process. This is compounded if multiple data sources are required for the same project. This needs to be factored in when planning to use EHR within RCTs and is best considered prior to conception of the trial. Data holders and researchers are endeavouring to simplify and streamline the application process so that the potential of EHR can be realised for clinical trials.

Citing Articles

Exploring the implementation of a data trust committee: a qualitative evaluation of processes and practices.

Iqbal S, Moniz S, Bennin F, Garavito G, de Koning R, Yu R Res Involv Engagem. 2025; 11(1):19.

PMID: 40050984 PMC: 11887347. DOI: 10.1186/s40900-025-00693-4.


Making administrative healthcare systems clinical data the future of clinical trials: lessons from BladderPath.

Mintz H, Dosanjh A, Parsons H, Sydes M, Bryan R, James N BMJ Oncol. 2025; 2(1):e000038.

PMID: 39886499 PMC: 11235014. DOI: 10.1136/bmjonc-2023-000038.


Accuracy of healthcare systems data for identifying cardiovascular outcomes after stroke due to intracerebral haemorrhage in the United Kingdom.

Hosking A, Stephen J, Drever J, Whiteley W, Sudlow C, Salman R Trials. 2024; 25(1):774.

PMID: 39550597 PMC: 11568574. DOI: 10.1186/s13063-024-08631-7.


Evaluation of venous thromboembolism risk assessment models for hospital inpatients: the VTEAM evidence synthesis.

Horner D, Davis S, Pandor A, Shulver H, Goodacre S, Hind D Health Technol Assess. 2024; 28(20):1-166.

PMID: 38634415 PMC: 11056814. DOI: 10.3310/AWTW6200.


Supportive Care in Pediatric Oncology: Opportunities and Future Directions.

Freedman J, Beeler D, Bowers A, Bradford N, Cheung Y, Davies M Cancers (Basel). 2023; 15(23).

PMID: 38067252 PMC: 10705083. DOI: 10.3390/cancers15235549.


References
1.
Mc Cord K, Salman R, Treweek S, Gardner H, Strech D, Whiteley W . Routinely collected data for randomized trials: promises, barriers, and implications. Trials. 2018; 19(1):29. PMC: 5765645. DOI: 10.1186/s13063-017-2394-5. View

2.
Appleyard S, Gilbert D . Innovative Solutions for Clinical Trial Follow-up: Adding Value from Nationally Held UK Data. Clin Oncol (R Coll Radiol). 2017; 29(12):789-795. DOI: 10.1016/j.clon.2017.10.003. View

3.
Shore B, Nasreddine A, Kocher M . Overcoming the funding challenge: the cost of randomized controlled trials in the next decade. J Bone Joint Surg Am. 2012; 94 Suppl 1:101-6. DOI: 10.2106/JBJS.L.00193. View

4.
Ford E, Boyd A, Bowles J, Havard A, Aldridge R, Curcin V . Our data, our society, our health: A vision for inclusive and transparent health data science in the United Kingdom and beyond. Learn Health Syst. 2019; 3(3):e10191. PMC: 6628981. DOI: 10.1002/lrh2.10191. View

5.
Langley R, Cafferty F, Alhasso A, Rosen S, Sundaram S, Freeman S . Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). Lancet Oncol. 2013; 14(4):306-16. PMC: 3620898. DOI: 10.1016/S1470-2045(13)70025-1. View